Benitec Biopharma

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Friday, November 17, 2023
Fireside, Webcast, Conference, RNA, Pharmaceutical industry, Online shopping, Benitec Biopharma

HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A.

Key Points: 
  • HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A.
  • Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday, November 30th, 2023 at 10:00 am ET.
  • A live webcast of the presentation will be accessible from the Investor section of Benitec’s website at ir.benitec.com .
  • An archived version of the webcast will be available in the Events section of the Investors page of Benitec’s website for 90 days following the event.

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Retrieved on: 
Monday, November 13, 2023
Natural history, Clinical, REB, Oropharyngeal dysphagia, Dysphagia, Safety, Research, Dispute board, Principal investigator, IND, FIH, FDA, Oculopharyngeal muscular dystrophy, HIV disease progression rates, RNA, Pharmaceutical industry, Nursing, Medical imaging, Health insurance, Cryptocurrency, OPMD, Benitec Biopharma

Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.

Key Points: 
  • Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.
  • Total Revenues for the quarter ended September 30, 2023, were $0 compared to $0 for the quarter ended September 30, 2022.
  • Total Expenses for the quarter ended September 30, 2023 were $5.9 million compared to $4.6 million for the quarter ended September 30, 2022.
  • The loss from operations for the quarter ended September 30, 2023, was $5.9 million compared to a loss of $4.6 million for the quarter ended September 30, 2022.

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, September 21, 2023
Oculopharyngeal muscular dystrophy, REB, Dysphagia, Natural history, Oropharyngeal dysphagia, Principal investigator, RNA-dependent RNA polymerase, Form 10-K, Research, RNA, Investigational New Drug, 52 Weeks Make A Year, HIV disease progression rates, FIH, Dispute board, FDA, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Clinical, Food, Safety, Nursing, Pharmaceutical industry, Medical imaging, Health insurance, Cryptocurrency, Benitec Biopharma, OPMD

HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2023. The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2023, with the U.S. Securities and Exchange Commission.

Key Points: 
  • The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2023, with the U.S. Securities and Exchange Commission.
  • Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.
  • In December 2022, Benitec began screening OPMD subjects at the lead clinical study site in the United States.
  • In January 2023, Benitec announced the enrollment of the first OPMD subject into the OPMD NH Study in the United States.

Reflect Scientific Inc. Announces Record-Breaking Freezer Order from a $40B BioPharma Company

Retrieved on: 
Wednesday, September 20, 2023
Trust, Temperature, Benitec Biopharma, Renewable energy

This landmark deal involves the provision of our state-of-the-art storage freezers to a premier BioPharma company with a market valuation of $40 billion.

Key Points: 
  • This landmark deal involves the provision of our state-of-the-art storage freezers to a premier BioPharma company with a market valuation of $40 billion.
  • The contract involves the supply of state-of-the-art storage freezers designed to secure and efficiently store crucial biological samples.
  • As part of our growth strategy and dedication to serving the BioPharma sector, Reflect Scientific Inc. is currently in the midst of discussions for several other contracts, with shipments slated for 2023-24.
  • This monumental order further solidifies Reflect Scientific Inc.'s position in the marketplace as a preferred partner for cold storage solutions.

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Retrieved on: 
Friday, August 11, 2023
Janus, Exercise, Benitec Biopharma, Attention, Montgomery Street, RNA-dependent RNA polymerase, Bangladesh Securities and Exchange Commission, RNA, Sale, Prospectus, Form, Security (finance)

The pre-funded warrants are immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.

Key Points: 
  • The pre-funded warrants are immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.
  • The common warrants are immediately exercisable at an exercise price of $3.86 per share of common stock and will expire on the fifth anniversary of such initial exercisable date.
  • In addition, Benitec has granted the underwriter a 30-day option to purchase an additional 2,331,606 shares of common stock and/or common warrants to purchase up to an additional 2,331,606 shares of common stock at the public offering price, less discounts and commissions.
  • The aggregate gross proceeds to Benitec from the public offering were approximately $30.9 million (after giving effect to the 458,134 additional shares of common stock and 458,134 additional common warrants sold pursuant to the underwriter’s partial exercise of its over-allotment option), prior to deducting underwriting discounts, commissions and other estimated offering expenses.

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

Retrieved on: 
Wednesday, August 9, 2023
Janus, Exercise, Benitec Biopharma, Attention, Montgomery Street, RNA-dependent RNA polymerase, RNA, Sale, Prospectus, Form, Security (finance)

The pre-funded warrants, if any, will be immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.

Key Points: 
  • The pre-funded warrants, if any, will be immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock.
  • The offering is expected to close on August 11, 2023, subject to customary closing conditions.
  • In addition, Benitec has granted the underwriter a 30 day option to purchase an additional 2,331,606 shares of common stock and/or common warrants to purchase up to an additional 2,331,606 shares of common stock at the public offering price, less discounts and commissions.
  • The aggregate gross proceeds to Benitec from the public offering are expected to be approximately $30 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses.

Flash Therapeutics Appoints Jérôme Bédier as President to Accelerate its Biopharmaceutical CDMO Business Development

Retrieved on: 
Thursday, July 6, 2023
Research, Medical Supplies, Genetics, Health Technology, Biometrics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Biopharmaceutical, GMP, DNA, Benitec Biopharma, RNA, Novasep, CDMO, Patient, Therapy, Vaccine

Jérôme Bédier, 49 years old, is an expert in the biomanufacturing and CDMO sector, to which he has devoted a large part of his career.

Key Points: 
  • Jérôme Bédier, 49 years old, is an expert in the biomanufacturing and CDMO sector, to which he has devoted a large part of his career.
  • With 25 years of experience, most particularly with the Novasep group, Jérôme Bédier held positions in business development and operations management before taking over strategic management of Novasep's Biopharmaceutical business and its three European sites.
  • "We are delighted to welcome Jérôme Bédier, an expert in biomanufacturing and service to the biopharmaceutical industry, to the executive management of Flash Therapeutics.
  • Jérôme Bédier added: "I am very pleased to join Flash Therapeutics in Toulouse.

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Retrieved on: 
Monday, June 26, 2023
Oculopharyngeal muscular dystrophy, Dysphagia, RNA-dependent RNA polymerase, OPMD, Data collection, RNA, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Benitec Biopharma, IND

Oculopharyngeal Muscular Dystrophy (OPMD) is a chronic, life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel.

Key Points: 
  • Oculopharyngeal Muscular Dystrophy (OPMD) is a chronic, life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel.
  • OPMD patients lose the ability to swallow liquids and solids, resulting in chronic malnutrition, aspiration, and fatal episodes of aspiration pneumonia.
  • Currently, there are no approved therapeutic agents for the treatment of OPMD.
  • “The FDA’s clearance of our IND for BB-301 is a significant milestone for OPMD patients and for Benitec as a Company,” said Jerel A.

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

Retrieved on: 
Monday, May 8, 2023
Benitec Biopharma, RNA-dependent RNA polymerase, Webcast, Child development stages, RNA, Conference, Vaccine, Online shopping

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

Key Points: 
  • HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
  • Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present at the JMP Securities Life Sciences Conference on Tuesday, May 16th, 2023 at 2:00 pm ET.
  • A live webcast of the presentation will be accessible from the Investor section of Benitec’s website at ir.benitec.com .
  • An archived version of the webcast will be available in the Events section of the Investors page of Benitec’s website for 90 days following the event.

Benitec Biopharma to Present at the OPMD International Conference

Retrieved on: 
Monday, May 8, 2023
Oculopharyngeal muscular dystrophy, Natural history study, RNA-dependent RNA polymerase, Child development stages, OPMD, RNA, International Conference on Nuclear Disarmament, Oslo, 2008, Conference, Safety, Pharmaceutical industry, Nursing, Benitec Biopharma

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

Key Points: 
  • HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.
  • Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present virtually on the BB-301 Clinical Development Program at the Oculopharyngeal Muscular Dystrophy (OPMD) International Conference in Tel Aviv, Israel, on Tuesday, May 16th, 2023 at 12:50 pm Israel Daylight Time.
  • Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec.
  • “Enrollment of OPMD subjects into the Natural History Study at the U.S. clinical trial site is proceeding at a rapid pace, with 9 subjects enrolled to date.